相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Medicine, General & Internal
Victoria Hall et al.
Summary: This study investigated the duration and effectiveness of immunity among healthcare workers in the United Kingdom. It found that two doses of the BNT162b2 vaccine provided high short-term protection against SARS-CoV-2 infection, but this protection significantly decreased after six months. However, infection-acquired immunity boosted by vaccination remained high, even more than one year after infection.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Letter
Medicine, General & Internal
Shirley Collie et al.
Summary: Preliminary data from a test-negative study design in South Africa showed that two doses of the BNT162b2 vaccine had an efficacy of 50 to 70% against hospitalization caused by the omicron variant in Gauteng province.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Ariel Hammerman et al.
Summary: This retrospective cohort study in Israel found that receiving at least one dose of the BNT162b2 vaccine was associated with a significantly lower risk of recurrent infection among patients who had recovered from Covid-19. Vaccine effectiveness was similar for one dose and two doses.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Letter
Rheumatology
Dennis G. McGonagle
LANCET RHEUMATOLOGY
(2022)
Review
Immunology
Jeffrey Cohen et al.
Summary: The likelihood and duration of reinfection with SARS-CoV-2 remain uncertain, as current knowledge on this topic is limited. Studies on other respiratory viruses suggest that serum antibodies typically persist for only a few months to a few years, making reinfections common. These findings have implications for vaccine development and the need for continued protective measures.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Biochemistry & Molecular Biology
Patrick Tang et al.
Summary: mRNA COVID-19 vaccines demonstrate high effectiveness in preventing severe outcomes and death caused by the Delta variant in Qatar, despite lower effectiveness at blocking infection.
Article
Biochemistry & Molecular Biology
Koen B. Pouwels et al.
Summary: A large, community-based study in the United Kingdom indicates that the effectiveness of BNT162b2 and ChAdOx1 vaccines against SARS-CoV-2 infections with symptoms or high viral burden is reduced with the Delta variant compared to the Alpha variant. Although the effectiveness of two doses is at least as great as protection afforded by prior natural infection, there are significant differences in the dynamics of immunity after the second dose between BNT162b2 and ChAdOx1.
Letter
Medicine, General & Internal
Laith J. Abu-Raddad et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Medicine, General & Internal
Hiam Chemaitelly et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Public, Environmental & Occupational Health
Philip A. Chan et al.
Summary: A cross-sectional survey conducted in Rhode Island in May 2020 found a statewide seroprevalence of SARS-CoV-2 antibodies at 2.1%. The prevalence was notably higher among Hispanics/Latinos and African Americans/Blacks. The study highlights the importance of continued monitoring and population-based sampling to understand the impacts of COVID-19 going forward.
AMERICAN JOURNAL OF PUBLIC HEALTH
(2021)
Article
Immunology
Valeria De Giorgi et al.
Summary: This study conducted a longitudinal analysis of COVID-19 convalescent plasma donors over an 11-month period, finding that most individuals maintained detectable levels of anti-SARS-CoV-2 IgG and neutralizing titers up to 11 months after symptom recovery. However, some donors experienced a decline in neutralization levels to undetectable titers over time.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Public, Environmental & Occupational Health
Alyson M. Cavanaugh et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2021)
